Mark Hellreich
Internal Medicine · Asheville, NCNPI 1396831830
Payments from drug & device makers
Across 213 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$833
- Boehringer Ingelheim$546
- Grifols USA, LLC$457
- AstraZeneca$385
- Regeneron Healthcare Solutions, Inc.$217
- Actelion Pharmaceuticals US, Inc.$179
- plus $877 from 12 others
What the payments were for
- Food & beverage$3,47399%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 60 | $833 |
| Boehringer Ingelheim | 26 | $546 |
| Grifols USA, LLC | 33 | $457 |
| AstraZeneca | 22 | $385 |
| Regeneron Healthcare Solutions, Inc. | 10 | $217 |
| Actelion Pharmaceuticals US, Inc. | 9 | $179 |
| Sanofi | 8 | $155 |
| Sunovion Pharmaceuticals Inc. | 8 | $132 |
| Genentech USA, Inc. | 8 | $127 |
| Mylan Specialty L.p. | 7 | $113 |
| Insmed, Inc. | 7 | $110 |
| Astellas Pharma US Inc | 4 | $49 |
| Pfizer | 4 | $47 |
| United Therapeutics Corporation | 2 | $46 |
| Mallinckrodt Hospital Products Inc. | 2 | $40 |
| CSL Behring | 1 | $20 |
| Novartis | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
How this compares
$3,493 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 236 | $176,388 |
| Spiriva RespimatTiotropium Bromide | 74 | $57,898 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $35,132 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $25,894 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $21,626 |
| Arnuity ElliptaFluticasone Furoate | 44 | $16,351 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $8,532 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,522 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 197 | $5,548 |
| Montelukast Sodium | 438 | $4,831 |
| Azelastine Hcl | 93 | $4,212 |
| Ventolin HfaAlbuterol Sulfate | 51 | $2,782 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,777 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,675 |
| Fluticasone Propionate | 42 | $763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $833 | $240,260376 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $546 | $64,42086 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $385 | $43,66372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Asheville
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.